The Importance of Early Manufacturing Decisions for Building a Commercially-Scalable Personalised, Precision T Cell Therapy

Time: 2:30 pm
day: Conference Day 2


  • Addressing the challenges of cell therapy manufacturing by investing early in the design of a fully-closed and automated process for industrial scale-up
  • Building a scalable and automated process to support large scale expansion and a reduction in manufacturing timelines and costs
  • Strategies for designing a clonal neoantigen T cell therapy (cNeT) with specificity for multiple targets and maintaining potency and fitness